160 related articles for article (PubMed ID: 29292064)
1. In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial.
Garcia-Garcia HM; Haude M; Kuku K; Hideo-Kajita A; Ince H; Abizaid A; Tölg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Escaned J; Dijkstra J; Waksman R
Int J Cardiol; 2018 Mar; 255():22-28. PubMed ID: 29292064
[TBL] [Abstract][Full Text] [Related]
2. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.
Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Garcia-Garcia HM; Waksman R
Lancet; 2016 Jan; 387(10013):31-9. PubMed ID: 26470647
[TBL] [Abstract][Full Text] [Related]
3. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.
Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Onuma Y; Garcia-Garcia HM; Waksman R
Eur Heart J; 2016 Sep; 37(35):2701-9. PubMed ID: 27190094
[TBL] [Abstract][Full Text] [Related]
4. First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study.
Hideo-Kajita A; Garcia-Garcia HM; Haude M; Joner M; Koolen J; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Teik LS; Escaned J; Azizi V; Kuku KO; Ozaki Y; Dan K; Waksman R
Cardiovasc Revasc Med; 2019 May; 20(5):392-398. PubMed ID: 31079817
[TBL] [Abstract][Full Text] [Related]
5. Impact of procedural characteristics on coronary vessel wall healing following implantation of second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary artery lesions: an optical coherence tomography analysis.
Ozaki Y; Garcia-Garcia HM; Hideo-Kajita A; Kuku KO; Haude M; Ince H; Abizaid A; Tölg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Escaned J; Dijkstra J; Waksman R
Eur Heart J Cardiovasc Imaging; 2019 Aug; 20(8):916-924. PubMed ID: 30590578
[TBL] [Abstract][Full Text] [Related]
6. Serial 3-Dimensional Optical Coherence Tomography Assessment of Jailed Side-Branch by Second-Generation Drug-Eluting Absorbable Metal Scaffold (from the BIOSOLVE-II Trial).
Ozaki Y; Garcia-Garcia HM; Hideo-Kajita A; Kuku KO; Haude M; Ince H; Abizaid A; Tölg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Escaned J; Waksman R
Am J Cardiol; 2019 Apr; 123(7):1044-1051. PubMed ID: 30683424
[TBL] [Abstract][Full Text] [Related]
7. Serial observation of drug-eluting absorbable metal scaffold: multi-imaging modality assessment.
Waksman R; Prati F; Bruining N; Haude M; Böse D; Kitabata H; Erne P; Verheye S; Degen H; Vermeersch P; Di Vito L; Koolen J; Erbel R
Circ Cardiovasc Interv; 2013 Dec; 6(6):644-53. PubMed ID: 24254708
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
[TBL] [Abstract][Full Text] [Related]
9. Neointimal Healing Evaluated by Optical Coherence Tomography after Drug-Eluting Absorbable Metal Scaffold Implantation in de novo Native Coronary Lesions: Rationale and Design of the Magmaris-OCT Study.
Karjalainen P; Paana T; Sia J; Nammas W
Cardiology; 2017; 137(4):225-230. PubMed ID: 28467998
[TBL] [Abstract][Full Text] [Related]
10. Serial invasive imaging follow-up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold.
Tovar Forero MN; van Zandvoort L; Masdjedi K; Diletti R; Wilschut J; de Jaegere PP; Zijlstra F; Van Mieghem NM; Daemen J
Catheter Cardiovasc Interv; 2020 Feb; 95(2):226-231. PubMed ID: 31033171
[TBL] [Abstract][Full Text] [Related]
11. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.
Haude M; Erbel R; Erne P; Verheye S; Degen H; Böse D; Vermeersch P; Wijnbergen I; Weissman N; Prati F; Waksman R; Koolen J
Lancet; 2013 Mar; 381(9869):836-44. PubMed ID: 23332165
[TBL] [Abstract][Full Text] [Related]
12. Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.
Haude M; Ince H; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Eeckhout E; Garcia-Garcia HM; Waksman R
EuroIntervention; 2020 Feb; 15(15):e1375-e1382. PubMed ID: 30803936
[TBL] [Abstract][Full Text] [Related]
13. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
[TBL] [Abstract][Full Text] [Related]
14. Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 Years.
Haude M; Toelg R; Lemos PA; Christiansen EH; Abizaid A; von Birgelen C; Neumann FJ; Wijns W; Ince H; Kaiser C; Lim ST; Escaned J; Eeckhout E; Garcia-Garcia HM; Waksman R
Cardiovasc Revasc Med; 2022 May; 38():106-110. PubMed ID: 34364807
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
[TBL] [Abstract][Full Text] [Related]
16. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
Serruys PW; Onuma Y; Garcia-Garcia HM; Muramatsu T; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Ormiston JA
EuroIntervention; 2014 Mar; 9(11):1271-84. PubMed ID: 24291783
[TBL] [Abstract][Full Text] [Related]
18. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
[TBL] [Abstract][Full Text] [Related]
19. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
20. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
